经审核，公司监事会认为：公司编制的《募集说明书》符合法律法规和中国 证券监督管理委员会、上海证券交易所的相关规定，《募集说明书》的内容真实、 准确、完整，不存在虚假记载、误导性陈述或者重大遗漏。 成都圣诺生物科技股份有限公司（以下简称"公司"）监事会根据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司证券发行注册管理办法》 《公开发行证券的公司信息披露内容与格式准则第 61 号——上市公司向特定对 象发行证券募集说明书和发行情况报告书》等法律、法规和规范性文件的要求， 认真审核了公司编制的《成都圣诺生物科技股份有限公司以简易程序向特定对象 发行股票募集说明书》（以下简称《募集说明书》）。 成都圣诺生物科技股份有限公司监事会 对募集说明书真实性、准确性、完整性的审核意见 成都圣诺生物科技股份有限公司 监事会 1 2023 年 10 月 17 日 ...

Group 1: Company Overview - Chengdu Saintno Biological Technology Co., Ltd. was established in July 2001 and is recognized as a high-tech enterprise in Sichuan Province [1] - The company specializes in providing CDMO services for peptide drugs, establishing a comprehensive R&D pipeline and full industry chain platform in the domestic peptide drug field [1] - The company has accumulated a high reputation, providing pharmaceutical research services for over 40 projects, with 1 product approved for commercialization and 19 peptide innovative drugs entering clinical trials [1] Group 2: Financial Performance - In the first half of the year, the company's net profit increased; however, the net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, decreased by 38.18% to 9.2579 million yuan [2] - The decline was primarily due to an increase in financial expenses from a new loan of 150 million yuan, along with rising management costs and expenses related to the disposal of non-recoverable organic solvents and packaging [2] Group 3: Market Position and Strategy - The company is one of the most powerful peptide R&D and production enterprises in China, focusing on developing peptide generic drugs with significant market potential [2] - The company has a range of active pharmaceutical ingredients (APIs) including Enfuvirtide, Bivalirudin, and Liraglutide, among others, and is continuously selecting peptide generic drugs for development based on market opportunities [3] Group 4: Technological Advancements - The company has developed long-chain peptide conjugation technology, which enhances coupling efficiency and product quality, allowing for large-scale automated production of long-chain peptide drugs [4] - The PEGylation technology used for drugs like Exenatide has extended the half-life by over 50 times, reducing the dosing frequency to once a week, significantly improving patient convenience [4] Group 5: Regulatory and Competitive Landscape - The successful consistency evaluation of Cabergoline injection reflects the company's comprehensive strength in R&D, production, and quality management, positively impacting future product competitiveness and operational performance [4]

证券代码：688117 证券简称：圣诺生物 公告编号：2023-056 成都圣诺生物科技股份有限公司 关于持股 5%以上股东权益变动超过 1%的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次权益变动后，成都圣诺生物科技股份有限公司（以下简称"公司"） 股东乐普（北京）医疗器械股份有限公司（以下简称"信息披露义务人"或"乐 普医疗"）持有公司的股份数量为 6,161,445 股，占公司总股本的比例由 8.1000% 减少至 5.5013%。 本次权益变动未触及要约收购，不会导致公司控股股东、实际控制人发 生变化，不会对公司治理结构及持续经营产生影响。 公司于近日收到公司股东乐普医疗出具的书面通知，现将其有关权益变动情 况公告如下： 一、本次权益变动基本情况 （一）信息披露义务人基本情况 （5）主要股东：中国船舶重工集团公司第七二五研究所（洛阳船舶材料研 究所）持有其 12.98% 股份，蒲忠杰持有其 12.13% 股份， WP MEDICAL TECHNOLOGIES,INC 持有其 6.5 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2023-053 成都圣诺生物科技股份有限公司 关于自愿披露卡贝缩宫素注射液通过注射剂 仿制药质量和疗效一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都圣诺生物科技股份有限公司（以下简称"公司"）全资子公司成都圣诺 生物制药有限公司于近日收到国家药品监督管理局（以下简称"国家药监局"） 核准签发的关于卡贝缩宫素注射液的《药品补充申请批准通知书》，现将相关情 况公告如下： 一、药品基本情况 药品名称：卡贝缩宫素注射液/Carbetocin Injection 剂型：注射剂 规格：1ml：100µg 注册分类：化学药品 原药品批准文号：国药准字 H20163001 上市许可持有人：成都圣诺生物制药有限公司 1 防子宫收缩乏力和产后出血，于 1984 年在我国上市，目前卡贝缩宫素注射液进 入我国医保乙类目录。公司卡贝缩宫素注射液系国内首仿品种，2019 年国内市 场份额超过 20%，仅次于辉凌制药的原研产品。 三、对公司的影响 卡贝缩宫素注射液通过注射剂 ...

民生证券股份有限公司 | 序号 | 工作情况 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制 | 保荐机构已建立健全并有效执行了持续督 | | 1 | 度，并针对具体的持续督导工作制定相 | 导制度，并制定了相应的工作计划。 | | | 应的工作计划。 | | | | 根据中国证监会相关规定，在持续督导 | | | | 工作开始前，与上市公司或相关当事人 | 保荐机构已与公司签订《保荐协议》，该协 | | 2 | 签署持续督导协议，明确双方在持续督 | 议明确了双方在持续督导期间的权利和义 | | | 导期间的权利义务，并报上海证券交易 | 务，并报上海证券交易所备案。 | | | 所备案。 | | | | 通过日常沟通、定期回访、现场检查、 | 保荐机构通过日常沟通、定期或不定期回 | | 3 | | 访、现场办公及走访等方式，对公司开展持 | | | 尽职调查等方式开展持续督导工作。 | 续督导工作。 | | | 持续督导期间，按照有关规定对上市公 | | | | 司违法违规事项公开发表声明的，应于 | 本持续督导期间，公司未发生按有关规定需 | | ...

成都圣诺生物科技股份有限公司独立董事 关于第四届董事会第十次会议相关事项的独立意见 根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》等 法规以及《成都圣诺生物科技股份有限公司章程》《独立董事制度》等公司制度 的规定，我们作为成都圣诺生物科技股份有限公司（以下简称"公司"）的独立 董事，本着对公司及全体股东负责的态度，基于审慎独立判断的立场，认真审阅 了公司第四届董事会第十次会议的相关议案，现发表独立意见如下： 一、《关于公司向兴业银行股份有限公司成都分行申请 15,000 万元人民币 最高综合授信额度及接受关联方担保的议案》的独立意见 经核查，同意公司向兴业银行股份有限公司成都分行申请总额度不超过人民 币 15,000 万元的综合授信，授信期限一年，最终授信额度以银行实际审批的授 信额度为准，该授信额度在授信期限内可循环使用。本次向银行申请授信额度是 根据公司经营计划及融资需求，满足日常经营和业务顺利开展而进行的，不会对 公司经营、财务状况产生不利影响，不存在损害公司或其他股东、特别是中小股 东利益的情形，符合《上海证券交易所科创板股票上市规则》《上海证券交易所 科创板上市公司自律监管指引第 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2023, representing a 20% increase compared to the same period last year[1]. - The company expects a revenue guidance of 1.2 billion CNY for the full year 2023, which would mark a 25% year-over-year growth[1]. - The company reported a revenue of RMB 1.5 billion for the first half of 2023, representing a 20% increase year-over-year[12]. - The company expects a revenue guidance of RMB 3 billion for the full year 2023, indicating a projected growth of 25% compared to 2022[12]. - The company's operating revenue for the first half of 2023 was ¥173,833,824.96, representing a 3.78% increase compared to ¥167,510,229.44 in the same period last year[21]. - The net profit attributable to shareholders for the same period was ¥20,148,134.88, an increase of 8.09% from ¥18,640,527.67 year-on-year[21]. - The company reported a total revenue of 18,210.00 million RMB, with a net profit of 1,559.61 million RMB, reflecting a significant increase compared to the previous period[68]. - The net profit attributable to the parent company was 20.15 million yuan, up 8.09% year-on-year[88]. User Growth - User data indicates a growth in active users by 15%, reaching 1.2 million users by the end of June 2023[1]. - User data indicates a growth in active users by 15%, reaching a total of 3 million users by June 30, 2023[12]. Research and Development - Research and development expenses increased by 30% to 100 million CNY, reflecting the company's commitment to innovation[1]. - The company has established partnerships with two leading research institutions to enhance its R&D capabilities[1]. - The company has a strong emphasis on R&D investment, continuously innovating to meet the market demand for peptide pharmaceuticals[30]. - The company has developed 16 self-researched peptide raw materials, with 11 varieties obtaining production licenses or activation records in the domestic market[34]. - The company has achieved significant progress in R&D, with multiple products passing consistency evaluations and several raw materials submitted for market registration[58]. - The R&D personnel count increased to 215, representing 21.84% of the total workforce, up from 19.68% the previous year[70]. - The company has 11 R&D products submitted for registration with the National Medical Products Administration, and 19 projects in mid-to-long-term research[72]. Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[1]. - The company is actively pursuing new product development and market expansion strategies to enhance its competitive position in the pharmaceutical industry[36]. - The company has established partnerships with well-known pharmaceutical enterprises such as Fresenius, Masung, and Yangtze River Pharmaceutical Group, expanding its market presence in Europe, the United States, and South Korea[36]. Product Development - New product launches in the pipeline include three innovative biopharmaceuticals expected to enter the market by Q4 2023[1]. - The company is currently in the clinical phase III for its new diabetes drug, with expected market approval by Q4 2023[12]. - A new peptide-based drug is under development, with a projected launch date in early 2024[12]. - The company is focusing on expanding its product pipeline in areas such as oncology, chronic hepatitis B, diabetes, obstetrics, digestive system, and immune system diseases[78]. Financial Management - The company has approved a share buyback program of up to 50 million CNY to enhance shareholder value[1]. - The company has invested RMB 200 million in new technology for drug manufacturing, aiming to improve production efficiency by 30%[12]. - The company has received domestic approval for multiple raw materials, including Enfuvirtide for HIV treatment and Bivalirudin for anticoagulation during PCI procedures[35]. Environmental Responsibility - The company has established an environmental protection mechanism and is classified as a key pollutant discharge unit[114]. - The company emphasizes sustainable development and environmental protection, implementing a waste management system and utilizing advanced treatment processes for wastewater and waste gas[125]. - The company has received environmental impact assessment approvals for multiple projects, including the peptide drug production line and waste solvent comprehensive utilization technology renovation project[119]. Shareholder Commitments - The controlling shareholder, Sino Investment, commits to not transferring or entrusting the management of shares for 36 months post-listing, with a lock-up extension of 6 months if share price falls below the issue price for 20 consecutive trading days[137]. - The company will not reduce shares if under investigation by the China Securities Regulatory Commission or if publicly reprimanded by the stock exchange within the last 3 months[139]. - The employee stock ownership platform, Saint No Management, also adheres to a 36-month lock-up period and similar reduction commitments post-lock-up[143]. Related Party Transactions - The company has disclosed related party transactions, including the purchase of liquid phase chromatographs for approximately CNY 3,497,176.20[179]. - The total amount of related party transactions for 2022 was confirmed to be RMB 84.6415 million, exceeding the previously estimated total by RMB 0.6915 million[180]. Strategic Investments - The company invested a total of RMB 15 million in Chengdu Yuansheng Kechuang Angel Venture Capital Partnership, accounting for 12.24% of the registered capital of RMB 122.5 million, with the first phase investment of RMB 6 million made in June 2023[96]. - The company plans to apply for a bank credit facility of up to RMB 30 million for its wholly-owned subsidiary, with a guarantee amount of up to RMB 3 million[186].

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 成都圣诺生物科技股份有限公司（以下简称"公司"）第四届监事会第九次 会议通知于 2023 年 8 月 8 日以电话及邮件方式向各位监事发出，并于 2023 年 8 月 17 日在公司会议室以现场方式召开。会议由监事会主席曾德志先生召集和主 持。本次会议应出席监事 3 人，实际出席监事 3 人。本次会议的召集和召开程序 符合有关法律、法规、规范性文件和《成都圣诺生物科技股份有限公司章程》（以 下简称"《公司章程》"）的有关规定。 证券代码：688117 证券简称：圣诺生物 公告编号：2023-050 成都圣诺生物科技股份有限公司 第四届监事会第九次会议决议公告 二、监事会会议审议情况 经与会监事审议，做出如下决议： （一）审议通过《关于<公司 2023 年半年度报告及其摘要>的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 特此公告。 成都圣诺生物科技股份有限公司 监事会 2023 年 8 月 18 日 （二）审议通过《关于<公司 2023 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2023-051 成都圣诺生物科技股份有限公司 具体情况如下： 单位：人民币万元 关于2023年半年度募集资金存放与实际使用情况 的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》（证监会公告〔2022〕15 号）、《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》及相关格式指引的要求，成都圣诺 生物科技股份有限公司（以下简称"公司"或"圣诺生物"）董事会就 2023 年 半年度募集资金存放与实际使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金的金额及到账情况 经中国证券监督管理委员会《关于同意成都圣诺生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕1497 号）同意注册，公司获准 向社会公众公开发行人民币普通股（A 股）20,000,000 股，每股面值人民币 1 元，每股发行价为人民币 17.90 元， ...